These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8971438)

  • 1. Improved tolerability of ritonavir derived from pharmacokinetic principles.
    Merry C; Barry M; Gibbons S; Mulcahy F; Back D
    Br J Clin Pharmacol; 1996 Dec; 42(6):787. PubMed ID: 8971438
    [No Abstract]   [Full Text] [Related]  

  • 2. [Overcoming weaknesses in therapy. Protease inhibitors with high IQ].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():96-7. PubMed ID: 11373795
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approves new dosing for amprenavir and ritonavir combination.
    AIDS Treat News; 2002 Mar; (378):6-7. PubMed ID: 11965920
    [No Abstract]   [Full Text] [Related]  

  • 4. [No resistance even after 1 year. New drug combination against HIV].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():108. PubMed ID: 11373766
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
    Sekar V; Kestens D; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2007 Apr; 47(4):479-84. PubMed ID: 17389557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.
    Sherman EM; Steinberg JG
    Expert Opin Pharmacother; 2011 Jan; 12(1):141-8. PubMed ID: 21142696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients.
    Mir O; Dessard-Diana B; Louet AL; Loulergue P; Viard JP; Langlois A; Durdux C; Le Beller C
    Br J Clin Pharmacol; 2010 Jan; 69(1):99-101. PubMed ID: 20078618
    [No Abstract]   [Full Text] [Related]  

  • 11. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
    Kakuda TN; Opsomer M; Timmers M; Iterbeke K; Van De Casteele T; Hillewaert V; Petrovic R; Hoetelmans RM
    J Clin Pharmacol; 2014 Aug; 54(8):949-57. PubMed ID: 24644095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P
    J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy].
    MMW Fortschr Med; 2000; 142(3 Suppl):41. PubMed ID: 11012293
    [No Abstract]   [Full Text] [Related]  

  • 15. Ritonavir (Norvir).
    Porche DJ
    J Assoc Nurses AIDS Care; 1997; 8(6):81-3. PubMed ID: 9356969
    [No Abstract]   [Full Text] [Related]  

  • 16. From grapefruit juice to ritonavir.
    TreatmentUpdate; 2001; 12(12):5-6. PubMed ID: 11570093
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients.
    Boffito M; Jackson A; Pozniak A; Giraudon M; Kulkarni R; Abelardo MC; Patel IH; Morcos PN
    Drugs R D; 2015 Mar; 15(1):141-53. PubMed ID: 25742730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
    Boffito M; Miralles D; Hill A
    HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
    Sekar VJ; Lefebvre E; Guzman SS; Felicione E; De Pauw M; Vangeneugden T; Hoetelmans RM
    Antivir Ther; 2008; 13(4):563-9. PubMed ID: 18672535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.